Improvements in outcomes for patients with resectable lung cancers have plateaued.
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …

The aim of this study is to report assemblage of a large multi-institutional international
database of esophageal cancer patients, patient and tumor characteristics, and survival of …

BACKGROUND: This study evaluates the utility of positron emission tomography (PET),
endoscopic ultrasonography (EUS), and computed tomographic (CT) scans to predict …

Background Evidence from retrospective studies suggests that disease progression after first-
line chemotherapy for metastatic non-small-cell lung cancer (NSCLC) occurs most often at …

PURPOSE Our previously published findings reported that local consolidative therapy (LCT)
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

BACKGROUND: Preclinical studies in animal models have demonstrated tumor regression
following intratumoral administration of an adenovirus vector containing wild-type p53 …

Object. Anterior approaches to the spine for the treatment of spinal tumors have gained
acceptance; however, in most published reports, patients with primary, metastatic, or chest …

Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a
single entity with predictably poor results. Using tumor expression data and non-negative …